GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $1,021,160.89 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,559 shares of GeneDx stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the completion of the sale, the chief executive officer now owns 14,865 shares of the company’s stock, valued at $1,437,594.15. The trade was a 41.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Performance

Shares of NASDAQ:WGS opened at $97.44 on Thursday. The firm has a fifty day simple moving average of $84.59 and a two-hundred day simple moving average of $70.97. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $2.73 billion, a P/E ratio of -49.71 and a beta of 1.91. GeneDx Holdings Corp. has a 52 week low of $8.03 and a 52 week high of $115.60.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. On average, analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on WGS. The Goldman Sachs Group upped their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen lifted their target price on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of WGS. Principal Financial Group Inc. bought a new stake in GeneDx during the 3rd quarter valued at $604,000. GSA Capital Partners LLP bought a new stake in shares of GeneDx in the third quarter valued at about $322,000. Royce & Associates LP bought a new stake in shares of GeneDx in the third quarter valued at about $1,201,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in GeneDx in the third quarter worth about $2,547,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after acquiring an additional 110,666 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.